January 12, 2022
August 23, 2023
The New Alzheimer's Drug – Benefit Or Boondoggle?
Aducanumab (Aduhelm, Biogen) was fast-tracked through the FDA in June of 2021 receiving accelerated approval to treat mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD). People with more advanced stages of AD are not candidates for the drug although the FDA did not specify who should not receive it.
January 12, 2022
August 23, 2023
Read more